Vitamin E
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Vitamin E
- Vitamin E: From Vitamin Supplementation Indication to Inborn Disorder of Bilirubin Metabolism
Vitamin E: From Vitamin Supplementation Indication to Inborn Disorder of Bilirubin Metabolism
One-Sentence Summary
Vitamin E is a fat-soluble antioxidant nutrient for which no approved drug license or clearly defined approved indication has been identified in Taiwan. The TxGNN model predicts that it may have potential benefit for inborn disorder of bilirubin metabolism, but currently only 3 clinical trials (none directly testing Vitamin E in this disease) and 2 publications (both Tier 3 reviews/case reports) provide support, indicating weak evidence strength.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No data found (Taiwan Not marketed; no approved indication text) |
| Predicted New Indication | Inborn Disorder of Bilirubin Metabolism |
| TxGNN Prediction Score | 99.99% (rank 522) |
| Evidence Level | L4 (mechanism/preclinical level) |
| Taiwan Market Status | Not marketed |
| Number of Drug Licenses | 0 |
| Recommended Decision | Hold (deferred) |
Why is This Prediction Reasonable?
Currently no detailed Vitamin E mechanism of action (MOA) data is available (DG002, High severity gap). Based on existing public information, Vitamin E is a fat-soluble antioxidant vitamin whose efficacy in “Vitamin E deficiency” has been established; mechanistically, as a free radical scavenger, it could theoretically reduce lipid peroxidation and lower oxidative stress, thus being linked by the model to hepatobiliary metabolism-related diseases.
However, in inborn disorders of bilirubin metabolism (such as Crigler-Najjar syndrome, progressive familial intrahepatic cholestasis, etc.), the core pathophysiology is primary genetic defects of bilirubin-synthesizing enzymes or transport proteins, not oxidative stress-driven disease. Literature and trial evidence show that such patients frequently present with malabsorption of fat-soluble vitamins (including Vitamin E), so clinical Vitamin E supplementation typically aims to “correct secondary deficiency” rather than “treat primary metabolic defects.” The 3 listed clinical trials are also not designed to directly test Vitamin E intervention in this disease; the associations are indirect and the mechanistic reasoning awaits validation.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06465810 | N/A | Recruiting | 1,850 | International ATTR amyloidosis real-world registry study, encompassing a cohort with bilirubin metabolism disease, but not specifically testing Vitamin E intervention (relevance grade B) |
| NCT01556906 | Phase 2 | Completed | 6 | Dose-escalation trial of MTP inhibitor lomitapide in homozygous familial hypercholesterolemia; investigational drug is not Vitamin E, only indirectly related (relevance grade C) |
| NCT03115086 | N/A | Active, not recruiting | 55 | Post-marketing patient registry for Cholbam (cholic acid), collecting disease natural history data; not a drug intervention trial (relevance grade B) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7915305 | 1994 | Case report/Review | The Journal of Pediatrics | Describes a novel disease cause (3β-hydroxy-C27-steroid dehydrogenase/isomerase deficiency) leading to progressive familial intrahepatic cholestasis; this is a disease mechanistic descriptive publication, not a Vitamin E intervention study |
| 803225 | 1975 | Review | The New England Journal of Medicine | Review of unconjugated hyperbilirubinemia in newborns; no abstract available; no direct association with Vitamin E treatment |
Taiwan Market Information
No approved drug license data currently identified in Taiwan (market status: Not marketed; registration count: 0; no permit/indication text available for display).
Safety Considerations
Drug Interactions (source: DDInter; 173 interaction records identified total; excerpted below):
- Moderate grade (warrant attention; predominantly related to anticoagulation/antiplatelet agents and mineral absorption): Acetylsalicylic acid, Iron, Iron sucrose, Sevelamer, Abciximab, Antithrombin III human, Apixaban, Dipyridamole, Betrixaban, Bivalirudin, Cangrelor, Caplacizumab — high-dose Vitamin E could theoretically potentiate the bleeding risk of anticoagulant/antiplatelet drugs and may produce absorption-level interactions with iron products/phosphate binders.
- Minor grade: Hydrocortisone, Triamcinolone, Dexamethasone, Betamethasone, Budesonide, Orlistat, Prednisone, Prednisolone.
⚠️ Due to missing product information warnings and contraindication data (DG001, Blocking severity), a comprehensive safety initial assessment cannot be completed, which is a blocking gap for proceeding to the next phase.
Conclusion and Next Steps
Decision: Hold (deferred)
Rationale:
- The top-ranked predicted indication (inborn disorder of bilirubin metabolism) achieves only L4 (mechanism/preclinical) evidence level; the 3 existing trials are not designed to directly test Vitamin E in this disease, and the 2 publications are merely descriptive reviews/case reports, insufficient to support progression to the next stage of safety assessment.
- Missing product information warnings and contraindication data constitute a Blocking-level gap; per protocol, S1 safety initial assessment cannot be completed.
To proceed further, the following must be completed:
- TFDA product information warnings and contraindication data (download and parse official product information PDF)
- Complete Vitamin E mechanism of action (MOA) data (query the DrugBank API)
- Direct intervention human trial evidence for inborn disorder of bilirubin metabolism
Note: In the same Evidence Pack, the second-ranked indication “bilirubin metabolism disease (broad sense bilirubin metabolism disease, including NAFLD/NASH-related hepatic dysfunction)” achieves L2 evidence level, supported by one completed Phase 4 head-to-head RCT (Vitamin E vs UDCA vs pentoxifylline, n=102) and multiple observational cohorts; evaluation of the feasibility of advancing this indication is recommended as a separate agenda item.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.